Učitavanje...
CAR T Cell Therapy for Neuroblastoma
Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with debilitating long term sequelae from treatment. Even after integration of anti-GD2 monoclonal antibody therapy into standard, upftont protocols, 5-year overall survival rates are only about 50%. The success...
Spremljeno u:
| Izdano u: | Front Immunol |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6232778/ https://ncbi.nlm.nih.gov/pubmed/30459759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.02380 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|